Systemic treatment for pre-treated recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC): a comprehensive review of randomized phase III data

被引：0
|
作者：
Roets, Evelyne [1 ]
Govarts, Anouk [1 ]
van Gogh, Evelien [1 ]
Tukanova, Karina [1 ]
Specenier, Pol [1 ,2 ]
机构：
[1] Univ Antwerp, Antwerp, Belgium
[2] Antwerp Univ Hosp, Edegem, Belgium
来源：
ACTA CLINICA BELGICA | 2017年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0011
引用
收藏
页码：14 / 14
页数：1
相关论文
共 50 条
  • [21] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients (pts) with cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Bauman, J. E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] A REVIEW OF EPIDEMIOLOGY, PROGNOSIS, AND TREATMENT OPTIONS FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMAS (HNSCC)
    Blieden, M.
    Muszbek, N.
    Chaudhary, M. A.
    Zhang, Y.
    VALUE IN HEALTH, 2017, 20 (05) : A94 - A94
  • [23] Outcome of Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Post-Immune Checkpoint Inhibitor (ICI) Treatment
    Park, J. C.
    Merkin, R. D.
    Wirth, L.
    Patel, M. J.
    Roberts, T. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E41 - E41
  • [24] Safety analysis of a phase III randomized trial of chemotherapy with or without bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Argiris, Athanassios
    Li, Shuli
    Savvides, Panayiotis
    Forastiere, Arlene A.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the US
    Hanna, Glenn J.
    Zheng, Dandan
    Gao, Wei
    Hair, Gleicy M.
    Ai, Lei
    Song, Yan
    Lerman, Nati
    Bidadi, Behzad
    Zion, Abigail
    Zou, Lin
    Tang, Yuexin
    Wang, Liya
    Merchant, Sanjay
    Black, Christopher M.
    ORAL ONCOLOGY, 2025, 161
  • [26] Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)
    Hernando-Calvo, A.
    Mirallas, O.
    Marmolejo, D.
    Felip, E.
    Villacampa Javierre, G.
    Garralda, E.
    Gutierrez, R.
    Feliu, B.
    Martinez, S.
    Dienstmann, R.
    Brana, I.
    ANNALS OF ONCOLOGY, 2019, 30 : 25 - 25
  • [27] Locoregional vs. distant relapse: Impact on survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immunotherapy
    Alouani, E. L.
    Piram, L.
    Chaltiel, L.
    Rigal, S.
    Delord, J-P.
    Bastien, C.
    Gomez-Roca, C. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S801 - S802
  • [28] Comprehensive Geriatric Assessment and Quality of Life Aspects in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    Winter, Anna
    Schulz, Stefan M.
    Schmitter, Marc
    Mueller-Richter, Urs
    Kuebler, Alexander
    Kasper, Sylvia
    Hartmann, Stefan
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (17)
  • [29] Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study
    Zandberg, D. P.
    Algazi, A.
    Jimeno, A.
    Good, J.
    Fayette, J.
    Bouganim, N.
    Ready, N.
    Clement, P.
    Goswami, T.
    Jarkowski, A.
    Armstrong, J.
    Asubonteng, K.
    Melillo, G.
    Mesia, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 13 - 13
  • [30] Phase 2a Study of Cetuximab and Dasatinib in Patients With Cetuximab-Resistant Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
    Geiger, J. L.
    Egloff, A. M.
    Ohr, J.
    Stabile, L.
    Gooding, W.
    Flaherty, J.
    Gibson, M.
    Grandis, J.
    Bauman, J. E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 930 - 930
12345